142 results about "Human Adenoviruses" patented technology

The invention relates to a vaccine comprising an adenovirus vector and a vaccinia virus vector and an application of the vaccine in treating tumor. The vaccine comprises oncolytic adenovirus and vaccinia virus; the two viruses are used in sequence, wherein the oncolytic adenovirus is the reproductive human adenovirus type 5 and the vaccinia virus is the vaccinia virus for smallpox vaccine. According to the vaccine, the oncolytic adenovirus and the vaccinia virus are prepared into the vaccine by sequential combination, so the antineoplastic activity can be improved, the stronger cellular immune response can be generated compared with the effect of reversely associated virus or separate virus, the using effect is better and the long-term specific immunity of tumor is shown. The tumor vaccine can eradicate the tumor and generate the long-term specific immunity of tumor and can be used in the treatment of various tumors of the human or animals; and meanwhile, the vaccine can effectively prevent the tumor from relapsing and has a wide application prospect.

Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.

The invention discloses a kit for detecting B and E type human adenovirus nucleic acid and a detection method thereof. The kit for detecting the B and E type human adenovirus nucleic acid comprises RPA freeze-dried particles, an RPA reaction primer, an RPA reaction probe, an RPA buffer solution, a magnesium salt solution, a transverse flow test strip, a buffer solution, double distilled water and an adenovirus genome DNA. The kit for detecting the B and E type human adenovirus nucleic acid has the advantages that the transverse flow test strip is utilized for carrying out visual qualitative detection on an RPA nucleic acid amplification product, the whole reaction is carried out at the constant temperature of 38 DEG C, a stripe on the test strip can be observed by virtue of naked eyes within 5-20 minutes, results are read and discriminated, and a special detecting instrument is not needed during detection. The kit disclosed by the invention has the characteristics of high sensitivity, strong specificity, easiness in operation, quick reaction and portability of instruments and is especially applicable to bedside rapid diagnosis of adenovirus, epidemic prevention and disease control.

The invention discloses human adenovirus antigen epitope chimeric protein as well as preparation and application thereof, and relates to fields of gene engineering techniques, vaccines and diagnostic reagents. The amino acid sequences of hexon protein of type 3, type 7, type 11, type 14 and type 55 of adenovirus are analyzed through computer analysis, protein fragments with good antigenicity can be screened respectively, the fragments are connected by using two glycine and one serine, then chimeric protein with multiple antigen fragments in serial connection can be formed, pronucleus preferred codons are selected and interpreted into corresponding nucleotide sequences, and full-length genes can be synthesized in a chemical manner. The chimeric protein can be obtained through expression purification by using a gene engineering technique, and the chimeric protein comprises 363 amino acids in whole length. The expressed chimeric protein can be applied to vaccine research, HAdV antibody or antigen detection and the like, and is related to fields such as gene engineering techniques, vaccines and diagnostic reagents.

A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents.

The invention provides a single-chain antibody KGH-R1-ScFv for resisting p21Ras protein and application of the single-chain antibody KGH-R1-ScFv, belonging to the field of medical biology, and particularly relates to a recombination human adenovirus vector Ad-hrGFP-ScFv with a single-chain antibody coding gene KGH-R1-ScFv. The single-chain antibody provided by the invention can specifically recognise and perform antagonism to p21Ras proteins with different sources, different tissues and different cell strains in a broad-spectrum way, and also can inhibit the proliferation capacity and invasion capacity of human tumor cell of p21Ras protein with high expression in vitro, reduce the ratio of cells in cell division period, and inhibit the growth of transplantation tumor of human tumor cell of p21Ras protein with high expression in mice.

The invention discloses a method for preparing a neutralizing monoclonal antibody in a human adenovirus 7. The hexon fifth hypervariable region of a human adenovirus 3 vector is substituted by a hexon fifth hypervariable region gene of the human adenovirus 7 to construct a chimeric virus which is taken as an immunogen. A murine human adenovirus 7 neutralizing monoclonal antibody and a hybridoma cell strain 5MH5 / 3G5 prepared by using the method are further provided. A humanized and chimeric monoclonal antibody prepared by using the method and a medicinal composition comprising the humanized or human-mouse chimeric monoclonal antibody serving as an effective component are further provided. An exogenous neutralizing epitope is embedded into the hypervariable region of the human adenovirus 3 vector to construct a recombinant adenovirus showing the exogenous neutralizing epitope. By using the recombinant adenovirus as an immunogen, the exogenous neutralizing epitope can be shown effectively, the immune response effect is enhanced, and the research of a monoclonal antibody for treating infectious diseases is facilitated.

The present invention relates to the technical field of biomedicine, and mainly provides new uses of tauroursodeoxycholic acid, wherein the new uses comprise that the tauroursodeoxycholic acid inhibits the virus-entry-host cells adopting endocytosis so as to achieve prevention and treatment of virus infection, anti-injury, and anti-fibrosis. The present invention provides applications of the tauroursodeoxycholic acid in preparation of drugs for treatment of acute lung injury and pulmonary fibrosis, such that the application range of the tauroursodeoxycholic acid is broadened, and the new drug selection is provided for the virus infection patients. According to the present invention, it is confirmed that the tauroursodeoxycholic acid can effectively prevent and treat H5N1 avian influenza virus, human adenovirus and Zaire-type Ebola virus, and it is cleared that the pulmonary fibrosis prevention and control effect of the tauroursodeoxycholic acid is superior to the pulmonary fibrosis prevention and control effect of the chloroquine.

The invention discloses an adenovirus bivalent vaccine. The vaccine comprises a replication-deficient human adenovirus type 4 and a replication-deficient human adenovirus type 7. E1 and E3 genes of the replication-deficient human adenovirus type 4 and the replication-deficient human adenovirus type 7 are deleted, and partial coding frames of the E4 gene are replaced by corresponding coding framesof E4 gene of human adenovirus type 5. The vaccine can effectively stimulate an organism to generate a humoral immune response and a cellular immune response, generate specific neutralizing antibodieswith high titer, and is used for preventing infection of pathogens.

Previously, we showed that type I interferon (alpha / beta interferon [IFN-α / β]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 109 PFU of human adenovirus type 5 expressing porcine IFN-α (Ad5-pIFN-α) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-γ) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-α, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 108 PFU of Ad5-pIFN-α, low- or high-dose Ad5-pIFN-γ, or a combination of Ad5-pIFN-α and low- or high-dose Ad5-pIFN-γ and challenged all groups with FMDV 1 day later. The control group and the groups inoculated with either Ad5-pIFN-α or a low dose of Ad5-pIFN-γ developed clinical disease and viremia. However, the group that received the combination of both Ad5-IFNs with the low dose of Ad5-pIFN-γ was completely protected from challenge and had no viremia. Similarly the groups inoculated with the combination of Ad5s with the higher dose of Ad5-pIFN-γ or with only high-dose Ad5-pIFN-γ were protected. The protected animals did not develop antibodies against viral nonstructural (NS) proteins, while all infected animals were NS protein seropositive. No antiviral activity or significant levels of IFNs were detected in the protected groups, but there was an induction of some ISGs. The results indicate that the combination of type I and II IFNs act synergistically to inhibit FMDV replication in vitro and in vivo.